Drug profile · INN
amikacin sulfate
ARIKAYCE
amikacin sulfate (ARIKAYCE) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — amikacin sulfate
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
amikacin sulfate (ARIKAYCE) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is amikacin sulfate?
amikacin sulfate (ARIKAYCE) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for amikacin sulfate?
ARIKAYCE is a marketed brand name for amikacin sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amikacin sulfate?
amikacin sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.